arrow
J

Jo Southern

pfizer usa
H指数:34
被引数:5,625

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acute coronary syndrome after an infective exacerbation of COPD: a prospective cohort study of acute lower respiratory tract disease in hospitalised adults

COPD感染性急性加重后的急性冠状动脉综合征:一项针对住院成人急性下呼吸道疾病的队列研究

2025-12-150
PRE
Sensitivity of RSV detection by PCR in respiratory samples is not reduced by a 24 h delay from sampling to testing with storage at room temperature

呼吸道样本中通过PCR检测RSV的敏感性,不会因采样至检测的24小时延迟(在室温下储存)而降低。

2025-11-220
OAAI
Changes in carriage and serotype diversity of Streptococcus pneumoniae and other respiratory pathobionts in the UK between pre-PCV13 (2006-10), early-PCV13 (2010-12) and late-PCV13 (2012-23) periods

英国Streptococcus pneumoniae及其他呼吸道共生致病菌的携带率和血清型多样性变化,比较了PCV13接种前的时期(2006-2010年)、PCV13早期接种时期(2010-2012年)和PCV13晚期接种时期(2012-2023年)。

2025-09-180
OAAI
Non-pharmaceutical interventions for COVID-19 transiently reduced pneumococcal and Haemophilus influenzae carriage in a cross-sectional pediatric cohort in Southampton, UK

在英国南安普敦的横断面儿科队列中,对新型冠状病毒肺炎的非药物干预措施暂时减少了肺炎球菌和流感嗜血杆菌的携带

2024-08-061
OAAI
Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom
2023-02-0192
OA
Evaluation of Host Protein Biomarkers by ELISA From Whole Lysed Peripheral Blood for Development of Diagnostic Tests for Active Tuberculosis

通过ELISA从整个裂解的外周血中评估宿主蛋白质生物标志物,以开发活动性结核病的诊断测试

2022-05-208
OAAI
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
2022-03-0175
OAAI
Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study

在以色列通过接触者追踪确定的人群中,BNT162b2 mRNA新型冠状病毒肺炎疫苗对SARS-CoV-2变异体 β (B.1.351) 的有效性: 一项前瞻性队列研究

2021-12-0118
OAAI
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
2021-05-017
OAAI
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
LANCET
IF88.5
2021-05-011.2K
OAAI